Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Estrella Immunopharma, Inc. (ESLA)

Estrella Immunopharma receives Nasdaq bid price deficiency notice; 180 days to comply

Negative Impact 5 of 5 legal/regulatory Written later

Estrella Immunopharma received a Nasdaq notice on August 17, 2026, stating its common stock closed below $1.00 for 30 consecutive business days, so it no longer meets the minimum bid price requirement. The notice has no immediate effect on trading, and the company has until February 16, 2027 to regain compliance, which could involve a reverse stock split.

Key points

  • Nasdaq letter dated August 17, 2026 cites closing bid price below $1.00 from July 6, 2026 through August 14, 2026
  • Compliance period runs 180 calendar days, until February 16, 2027
  • Common stock continues to trade on The Nasdaq Capital Market under the symbol ESLA
  • If not compliant by the deadline, the company may be eligible for a second 180-day period, or face delisting notice and an appeal

The filing

CompanyEstrella Immunopharma, Inc. (ESLA)
Form8-K, current report
Filed with the SECAug 21, 2026, 5:00 PM ET
Accession number0001213900-26-092657

Items reported: 3.01 Delisting / Listing Rule Notice

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.